This information is intended for use by health professionals
Care Pholcodine 5mg/5ml Oral Solution Sugar Free
Pholcodine monohydrate 5.0mg/5ml
Excipients with known effect
This medicine contains, per 5ml dose:
5.625 Sodium Methyl Parahydroxybenzoate
0.75mg Sodium Propyl Parahydroxybenzoate
1.125mg Sodium Ethyl Parahydroxybenzoate
0.25mg Amaranth Dye
For the full list of excipients, see section 6.1.
A viscous red coloured liquid.
Cough suppressant for the relief of acute non-productive cough associated with upper respiratory tract infections.
For oral administration
Adult and children over 12 years:
One or two 5ml spoonfuls three or four times daily.
Not more than 4 doses should be given in any 24 hours
Adult dose is appropriate.
Do not exceed the stated dose.
Should not be administered to patients in or at risk of developing respiratory failure or during an attack of asthma.
Patients receiving monoamine oxidase inhibitors or within 2 weeks of cessation of their use.
Patients with chronic bronchitis, COPD, bronchiolitis or bronchiectasis due to sputum retention.
Known hypersensitivity to any of the ingredients.
Children under 12 years of age.
Should be used with caution in patients with renal, hepatic or respiratory disease, including a history of asthma. Galenphol and other cough suppressants may cause sputum retention and this may be harmful in patients with chronic bronchitis and bronchiectasis.
Caution is needed in patients with a history of drug abuse. Pholcodine is an opioid and addiction is observed with opioids as a class.
Ask a doctor before use if you suffer from a chronic or persistent cough, if you have asthma, are suffering from an acute asthma attack or where cough is accompanied by excessive secretions.
Use of pholcodine monohydrate with alcohol or other CNS depressants may increase the effects on the CNS and cause toxicity in relatively smaller doses.
Severe cutaneous adverse reactions (SCARs) including acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, have been reported in patients treated with this medicine, most likely in the first week. Patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, this medicine should be withdrawn immediately.
Ingredients with specified warnings
This medicine contains 48mg of alcohol (ethanol) in each 5ml dose. The amount in 5ml of this medicine is equivalent to less than 2ml of beer or 1ml of wine. The small amount of alcohol in this medicine will not have any noticeable effects.
It also contains less than 1mmol sodium (23mg) per 5ml dose, that is to say essentially 'sodium-free'.
It also contains sodium parahydroxybenzoates and amaranth dye which may cause allergic reactions (possibly delayed).
Keep out of the sight and reach of children.
Warning: Do not take more medicine than the label tells you to.
Do not take with other cough and cold medicines.
If symptoms persist consult your doctor.
Do not give to children under 12 years.
Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs:
Concomitant use of pholcodine and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe this medicine concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
Monoamine oxidase inhibitors: Galenphol should not be used within 14 days of treatment.
Interaction with neuromuscular blocking agents (anaphylaxis) has been reported.
The reduction of blood pressure caused by antihypertensives may accentuate the hypotensive effects of pholcodine monohydrate. Diuretics may have the same effect.
Pholcodine monohydrate may enhance the sedative effect of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives and tranquillisers (phenothiazines and tricyclic antidepressants).
Sedative medicines such as benzodiazepines or related drugs:
The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).
No data available on the use of Galenphol in pregnancy or lactation. Galenphol should only be used in pregnancy if considered necessary by the physician and should be avoided during the first trimester. Pholcodine monohydrate has been detected in human milk but in amounts unlikely to affect the suckling infant.
Using the dose recommended, it is not considered to be a hazard, however, the use of pholcodine monohydrate may cause sedation, dizziness and nausea. If affected, driving or operation of machinery would not be advised.
The following side effects may be associated with the use of pholcodine monohydrate:
Occasional drowsiness, dizziness, excitation, confusion, sputum retention, vomiting, gastrointestinal disturbances (nausea and constipation) and skin reactions including rash.
Skin and subcutaneous tissue Disorders: Frequency unknown: Acute generalised exanthematous pustulosis (see section 4.4).
Immune system disorders have been noted including hypersensitivity reactions and anaphylaxis.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
It is thought to be of low toxicity, but the effects in overdosage will be potentiated by simultaneous ingestion of alcohol and psychotropic drugs.
Symptoms of overdose include respiratory depression, nausea, drowsiness, restlessness, excitement and ataxia. Treatment should be symptomatic to maintain vital functions. Respiratory distress should be treated by supportive means. Airways protective gastric lavage may be used.
In severe cases a narcotic antagonist such as naloxone may be considered. Naloxone has been used successfully to reverse central or peripheral opioid effects in children (0.01mg/kg body weight). Other treatment option is activated charcoal (1g/kg body weight) if more than 4mg/kg has been ingested within 1 hour, provided the airway can be protected.
R05D A08 - Opium alkaloids and derivatives.
Galenphol contains pholcodine monohydrate which is a centrally acting cough suppressant. It has none of the other properties of opiate agents.
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
Citric acid monohydrate (E330)
Sodium methyl parahydroxybenzoate (E219)
Sodium ethyl parahydroxybenzoate (E215)
Sodium propyl parahydroxybenzoate
Amaranth dye (E123)
Condensed milk flavour
Two years from the date of manufacture.
Do not store above 25°C
200ml amber glass bottles with 28mm tamper evident child resistant closure with EPE/Saranex liner.
Amber HDPE 2 litre Winchester with a tamper evident polyethylene cap.
Thornton & Ross Ltd
30 August 2002